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ABSTRACT 
A functional -174 C/G polymorphism in the interleukin-6 gene (IL6) is a candidate to 
explain individual variations in exercise-related phenotypes. To replicate recent findings 
showing an association between the G allele and GG genotype of elite power sports 
performance in European (Spanish) Caucasian males (Ruiz et al. J Sci Med Sport, 
2010;13:549-53), we compared allelic and genotypic frequencies of the IL6 -174 C/G 
polymorphism among elite endurance athletes (N=74) and power athletes (N=81), and 
non-athletic controls (N=205) of both genders from Israel. All subjects were Israeli 
Caucasians [with an equivalent ratio of non-Ashkenazi and Ashkenazi descent in each 
group (2:1)]. We found no differences in the genotype or allele frequencies among 
groups (all P>0.3). We further compared the genotype and allele frequencies between 
national- (N=109) and international-level (N=46) Israeli athletes in the endurance and 
power group, and found no significant genotype or allele differences after adjusting for 
multiple comparisons. We repeated all the analyses after pulling together the Israeli and 
Spanish controls, endurance and power elite athletes, and found no genotypic and allelic 
differences among groups. The results did not change when the analyses were repeated 
including only the best Israeli athletes (i.e. the international level group) together with 
the group of elite Spanish athletes (P>0.2). In conclusion, the results of the present 
study did not show an association between the G allele of the IL6 -174 G/C 
polymorphism and power sports performance in the Israeli (Caucasian) population. Our 
findings support the need to replicate association results between genetic 
polymorphisms and athletic status in populations of different ethnic backgrounds with 
the largest possible population samples. 
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INTRODUCTION 
Interleukin-6 (IL-6) is not only involved in immune function (Amir et al., 2007), but 
also in muscle repair and hypertrophy following exercise-induced damage (Cantini et 
al., 1995; Helge et al., 2003; Weigert et al., 2007; McKay et al., 2008; Serrano et al., 
2008). A functional C/G polymorphism at position -174 [rs1800795] was described in 
the 5' flanking region of the IL-6 gene IL6 (Fishman et al., 1998), with the mutant G 
allele, rather than the wild-type C allele being associated with increased transcriptional 
response in vitro (Fishman et al., 1998; Terry et al., 2000) and in vivo conditions 
(Bennermo et al., 2004). The  IL6 -174 polymorphism is associated with numerous 
disease and disease-related phenotype traits such as cardiovascular disease (Sie et al., 
2006; Manginas et al., 2008; Panoulas et al., 2009), stroke (Tso et al., 2007), obesity 
comorbidities (Goyenechea et al., 2007), or fasting glucose levels (Huth et al., 2009). 
This genetic variation is also associated with exercise-related phenotypes.  
Ortlepp et al. found an association between the C allele and maximal work 
capacity in Caucasian smokers (Ortlepp et al., 2003). The -174 C/G variant was found 
to be associated with high-density lipoprotein cholesterol levels (Halverstadt et al., 
2005), glucose tolerance (McKenzie et al., 2004) and bone mass remodelling (Dhamrait 
et al., 2003) in response to exercise. Yamin et al. reported a strong association between 
the C allele of the IL6 -174 C/G polymorphism and skeletal muscle damage following 
eccentric contractions of the elbow flexor muscles in young adults (Yamin et al., 2008). 
Ruiz et al. recently demonstrated that the GG genotype and G allele are overrepresented 
in elite power athletes, for whom muscle hypertrophy/strength is a key phenotype trait, 
compared with elite endurance athletes and non-athletic controls (Ruiz et al., 2010b). 
Whether these results can be extrapolated to other populations remains to be elucidated. 
This is a question of interest because differences among the findings of studies in sports 
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genetics are partly attributable to between-studies differences in the size, gender and 
ethnic/geographic background of the cohorts. To replicate our recent findings (Ruiz et 
al., 2010b) we compared allelic and genotypic frequencies of IL6 -174 C/G 
polymorphism among elite endurance athletes and power athletes, and non-athletic 
controls from Israel. We also performed further replication analyses by pulling the two 
ethnic cohorts (i.e. Israeli and Spanish subjects) together. 
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METHODS 
Ethical approval 
The study was approved by the Helsinki Committee of the 'Hillel-Yaffe' Medical Center 
(Hadera, Israel) following the Declaration of Helsinki. Written informed consent 
was obtained from each participant. Our study was performed according to ethical  
standards in sport and exercise science research (Harriss & Atkinson, 2009). 
Subjects  
Israeli cohort. A total of 155 elite athletes (119 men and 36 women, age=35.9+12.2 yrs) 
volunteered to participate in the study. Athletes were included in the study sample only 
if they had participated in national (n=109) or international (n=49) track and field 
championships. Athletes were divided into two groups: i) endurance athletes (n=74, 20 
international level, which included long distance runners whose main event was the 
10,000m run and the marathon), and (ii) power athletes (n=81, 26 international level, 
which included sprinters whose main event was the 100-200m dash). Furthermore, we 
divided the athletes within each group into two subgroups according to their individual 
best performance: international athletes (those who had represented Israel in a world 
track-and-field championship or in the Olympic Games) and national-level athletes.  
The main characteristics of the Israeli athletes are shown in Table 1. The control group 
consisted of 205 non-athletic Israeli healthy individuals (167 men and 38 women, 
age=34.9+12) who did not engage in physical activity on a regular basis. All subjects 
(athletes and controls) were Israeli Caucasians. The Israeli population includes 
Caucasians with mixed Jews coming from Arab countries (non-Ashkenazi), and Jews 
coming from Europe (Ashkenazi). In the present study the ratio of non-Ashkenazi and 
Ashkenazi descent in each group (2:1).  
6 
 
Spanish cohort. As detailed elsewhere (Ruiz et al., 2010b), the Spanish population 
comprised:  
(i) 100 male world-class endurance athletes aged 20-39 (50 endurance runners and 50 
professional road cyclists). All the endurance runners (mostly specialists in 5,000m, 
10,000m and marathon) had participated in at least one Olympiad, and some were 
Olympic finalists or Europe/World Champions; the cyclists were all Tour de France 
finishers, including top-3 finishers. Their mean±SD maximal oxygen uptake (VO2max) 
was 73.7±5.7 ml·kg
-1
·min
-1
.  
(ii) 53 elite male power athletes aged 20-33 years (jumpers, throwers and sprinters). 
This group included 40 top national level and 13 Olympic level athletes. Their VO2max 
was 60.3±5.5 ml·kg
-1
·min
-1
.  
(iii) 100 healthy male non-athletic controls aged 19-32 years (VO2max: 50.1±2.6 ml·kg
-
1
·min
-1
). All were students from the same university (Universidad Europea de Madrid, 
Spain). Inclusion and exclusion criteria for this group were to be free of any diagnosed 
cardiorespiratory disease and not to be engaged in competitive sports or in formal, 
supervised exercise training (i.e. performing less than 3 structured weekly sessions of 
strenuous exercise as running, swimming, bicycling, and weight lifting).  
 All the subjects in this cohort were of the same Caucasian (Spanish) descent for 
≥3 generations. 
 
Genotyping 
Israeli cohort. We extracted genomic DNA from peripheral EDTA treated anti-
coagulated blood using a standard protocol. Genotyping was performed for research 
purposes based on the hypothesis that the IL6 -174 G/C polymorphism influences sports 
performance. The researchers in charge of genotyping were totally blinded to the 
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subjects’ identities as blood samples were tracked solely with bar-coding (Chanock et 
al., 2007).
 
We used the polymerase chain reaction (PCR). A 136-bp fragment of the IL-
6 -174 C and a 121 fragment of the IL-6 -174 G polymorphism were amplified using 3 
primers:  IL-6 GSP -F   5' ATAAATCTTTGTTGGAGGGTGAGG '3 and 
 IL-6 C -R     5' ATGACGACCTAAGCTTTACTTTTCCCCCTAGTTGTGTCTTGAC '3 
 IL-6 G -R 5' GCACTTTTCCCCCTAGTTGTGTCTTACG '3. The PCR was performed
 
by denaturation at 95°C for 10 min, 39 cycles of denaturation at 94°C for 30 sec, 
annealing
 
at 61°C for 45 sec, extension at 72°C for 1 min, and
 
a final extension step of  
7 min at 72°C. The
 
PCR products were then electrophoresed in a 4% agarose
 
gel. This 
method yields 136-bp fragments in the presence of the C allele, and 121-bp in the 
presence of the G allele. 
Spanish cohort. In the samples from Spanish subjects, genotyping was performed from 
saliva samples using a newly-developed low-density DNA microarray based on allele-
specific probes as previously described (Gomez-Gallego et al., 2010).  
 
Data analysis 
All statistical analyses were performed using the PASW (v. 18.0 for WINDOWS, 
Chicago). Using a χ2 test, we performed the comparisons that are described below. 
Israeli cohort. First, we compared genotype and allele frequencies of the IL6 -174 G/C 
polymorphism by sex within each of the following groups: controls, national level 
athletes (endurance and power together), international level athletes (endurance and 
power together), endurance athletes (both national and international level), power 
athletes (both national and international level), and non-Ashkenazi and Ashkenazi 
subjects. Second, we compared genotype and allele frequencies among controls, 
endurance and power athletes. We also repeated the analyses using only international 
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level athletes. Third, we further compared genotype and allele frequencies between 
national and international level athletes within the endurance and power group 
respectively.  
 
Israeli and Spanish cohorts. Finally, we repeated all the analyses after pulling together 
all the Israeli and Spanish controls, endurance and power elite athletes. We further 
conducted the analysis including only the best Israeli athletes (i.e. the international level 
group) together with the group of elite Spanish athletes. We used logistic regression 
analysis to determine the association between alleles and sports performance.  
In all analyses, multiple comparisons were adjusted for mass significance 
(Holm, 1979). 
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RESULTS 
There were no failures in sample collection, DNA acquisition or genotyping procedures. 
Genotype distributions met Hardy-Weinberg equilibrium in controls (P=0.931) and in 
endurance athletes (P=0.850), but not in the power athletes group (P=0.017). 
Genotype and allele frequencies did not differ by sex in any of the study groups 
(Table 2). Likewise, genotype and allele frequencies were similar between non-
Ashkenazi and Ashkenazi groups (χ2 = 0.07, P=0.9). 
Table 3 shows genotype and allele frequencies of the IL6 -174 
G/Cpolymorphism in controls, endurance and power athletes from Israel. There were no 
differences in genotype or allele frequencies among groups (all P>0.3). Likewise, there 
were no genotype and allele frequency differences when the analyses were repeated 
including only the international level group (Overall: χ2=2.741, P=0.602; χ2=2.069, 
P=0.355, respectively); endurance vs. power: (χ2=1.274, P=0.529; χ2=0.937, P=0.333, 
respectively) power vs. control: χ2=2.167, P=0.338; χ2=0.2.018, P=0.155, respectively; 
or endurance vs. control: χ2=0.615, P=0.735; χ2=0.004, P=0.951, respectively. When we 
further compared genotype and allele frequencies between national- and international-
levels athletes in the endurance and power group, we found no genotype or allele 
differences (Table 4). We repeated the analyses by comparing C carriers vs. non-C 
carriers in national and international level, and found no significant differences between 
groups (χ2=0.035, P=0.851; and χ2=2.952, P=0.086; in endurance and power athletes, 
respectively).  
Finally, to further confirm our findings, we repeated all the analyses after pulling 
together the Israeli and Spanish controls, endurance and power elite athletes. There were 
no genotype differences among groups (overall: χ2=8.593, P=0.072; control vs. 
endurance: χ2=8.593, P=0.072; controls vs. power: χ2=3.825, P=0.148; endurance vs. 
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power: χ2=5.850, P=0.054) (Figure 1). The odds ratio of being an elite power athlete if 
the subject had the G allele was 1.177 (95% confidence interval: 0.820-1.690) compared 
to the control group, and 1.329 (95% confidence interval: 0.900-1.961) compared to the 
endurance athlete group. The results did not change when the analyses were repeated 
including only the best Israeli athletes (i.e. only those of international level) together 
with the group of elite Spanish athletes (P>0.2). We repeated the analysis including the 
type of sport (cyclists or runners) as a covariate and the results remained the same (data 
not shown). It should be noted that there were between-country genotype and allele 
differences in the non-athlete and endurance athlete groups (all P<0.001), but not in the 
power athlete group (all P>0.1). 
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DISCUSSION 
The main finding of the present study was that the wild-type G allele of the IL6 -174 
G/C polymorphism is not associated with elite power athletic status in the Israeli 
population. Recent findings on a different Caucasian (Spanish) cohort, showing that the 
GG genotype and the G allele of the IL6 -174 G/C variant are overrepresented in elite 
power athletes compared with endurance athletes and sedentary controls (Ruiz et al., 
2010b) were not corroborated in the present study with a different population.   
The majority of published data in sports genetics comes from studies performed 
in European and North-American Caucasian populations. Our results support the need 
to replicate genotype:phenotype associations in this field of research with the largest 
possible cohorts, including populations of different ethnic backgrounds. Differences in 
the ethnic origin of the subjects might indeed help explain between-studies differences. 
This is well illustrated by the existing disparities on the possible influence of the 
insertion (I)/deletion (D) polymorphism in the angiotensin-converting enzyme (ACE) 
gene, arguably the most extensively studied polymorphism in sports genetics. In 
European Caucasians, the D allele has been associated with elite
  
performance in power-
oriented events, e.g., short-distance swimming (Woods et al., 2001; Costa et al., 2009), 
whereas the I allele seems to favour endurance events, e.g., running (Myerson et al., 
1999; Woods et al., 2001). In contrast, the D allele might be unfavourable for power 
athletic events in Koreans (Kim et al., 2010). Further, Amir et al. reported a positive 
association between ACE DD genotype and endurance (marathon) performance in the 
present athletic cohort (Amir et al., 2007). 
Besides the putative multifunctional role of IL6 gene, including modulation of 
body immune responses and muscle repair following damage, the rationale for studying 
the influence of the -174 G/C variation in exercise or disease phenotypes lies in the fact 
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that mutations/polymorphisms that are located in gene promoter regions can affect 
mRNA expression and protein levels (Yamin et al., 2008). The previous finding that the 
C allele is underrepresented in Spanish power athletes (Ruiz et al., 2010b) concurs with 
previous findings reported by Yamin et al. who indicated a strong, dose-dependent  
association between the C allele/CC genotype and increased muscle damage in response 
to unaccustomed eccentric exercise in non-athletes (Yamin et al., 2008). Both findings 
could be explained, at least partly, by the pivotal role that IL-6 plays on muscle repair 
and hypertrophy (Cantini et al., 1995; Helge et al., 2003; Weigert et al., 2007; Serrano 
et al., 2008; McKay et al., 2009) in response to acute exercise (Bamman et al., 2001; 
Yang & Goldspink, 2002; Tomiya et al., 2004; Mourkioti & Rosenthal, 2005; McKay et 
al., 2008; O'Reilly et al., 2008). However, in the present study allelic and genotypic 
frequencies were very similar in the three groups.  
The current finding that the IL6 -174 G/C polymorphism is not associated with 
endurance performance concurs with those by Ruiz et al. in Spanish athletes (showing 
no differences in the allelic or genotypic frequencies between elite endurance athletes 
and sedentary controls) (Ruiz et al., 2010b). Ortlepp et al. likewise observed similar 
levels of cardiorespiratory fitness levels in young male healthy non-smokers across IL6 
-174 G/C genotypes (Ortlepp et al., 2003). 
Finally, to determine those genetic polymorphisms that allow for excelling in 
power sports (vs. endurance events) across different ethnic groups as we did here is of 
potential interest for two reasons. First, elite athletes with a pure power oriented 
phenotype are not usually gathered in genotype:phenotype association studies. The 
majority of studies in the field have typically focused on endurance-related phenotype 
traits in North-American or European Caucasians. Yet, the ‘optimum’ genotype profile 
does probably differ between athletes excelling in endurance vs. more power-oriented 
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sports because the phenotype traits that determine performance in both types of events 
are likely different. For instance, in the Decathlon, performance by the world’s best 
competitors in 100m sprint or the long jump is negatively correlated with performance 
in the 1,500m race (Van Damme et al., 2002). We recently showed that it is very 
unlikely to find an individual with a genetic profile suitable to excel in both pure power 
and endurance oriented sport events (e.g., 100m race and marathon respectively) (Ruiz 
et al., 2010a). Secondly, humans are approaching locomotory limits in sprint races, 
which considerably reduces the ability of natural or artificial selection to produce faster 
athletes (Denny, 2008). Thus, given the difficulty to find more powerful athletes in 
coming generations, sports professionals worldwide might be interested in identifying 
those athletes who are endowed with the most suitable genetic profile to excel in 
competitive power sports.  
To note is that the genotype distributions of power athletes did not meet H-W 
equilibrium, as it was the case in a previous study of Spanish power athletes (Ruiz et al., 
2010b). There are several reasons that are likely to explain deviation from H-W 
expectations including genetic drift, migration, mutation (e.g. change in the rate of 
mutation from the C to the G allele of the IL6 -174 G/C polymorphism), selection, and 
non-random mating. It is however difficult to determine, without speculating, which of 
the aforementioned conditions occurred in our study.  
 
In summary, the results of the present study did not show an association between 
the G allele of the IL6 -174 G/C polymorphism and power sports performance in the 
Israeli (Caucasian) population. Previous data on a different cohort (Ruiz et al., 2010b), 
could not be corroborated with the present ethnic group. 
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Table 1. Main characteristics of the two athlete groups from Israel.  
 
Data are means ± standard deviation. 
Non-athletic (controls) Israeli healthy individuals included 167 men and 38 women. 
 
Sprinters (n=81): 
 Personal best 100m time
 
 
Endurance athletes (n=74): 
Personal best marathon time
 
 
 
Women (n=22) Men (n=59) Women (n=14) Men (n=60) 
 
11.80±0.1 s 
(n=11) 
10.43 ±0.15 s 
(n=15) 
2 h 44 min 20 s ± 3 min 
(n=6) 
2h 19 min 57 s ± 2 min 
(n=14) 
Elite-level  
(n=46) 
 
12.22±0.34 s 
(n=11) 
 
10.85± 0.26 s 
(n=44) 
 
3 h 5min 20 s  ± 35 min 
(n=8) 
 
2 h 44 min 6 s ± 25 min 
(n=46) 
 
National-level 
(n=109) 
20 
 
 Table 2. Genotype and allele frequencies by sex in the Israeli cohort. 
 
   Men   Women   P (χ2) 
Controls N % N % 
 
GG 122 73.1 25 65.8 0.662 (0.826) 
GC (41) 24.6 12 31.6 
 
CC (4) 2.4 1 2.6 
 
p (G) 
 
0.85 
 
0.82 0.413 (0.670) 
q  (C 
 
0.15 
 
0.18 
 
Endurance International 
    
GG 10 76.9 4 57.1 0.357 (0.848) 
GC 3 23.1 3 42.9 
 
CC - 
 
- 
  
p (G) 
 
0.88 
 
0.79 0.403 (0.698) 
q  (C 
 
0.12 
 
0.21 
 
Power International 
     
GG 7 46.7 8 72.7 0.126 (4.149) 
GC 8 53.3 2 18.2 
 
CC - 
 
1 9.1 
 
p (G) 
 
0.73 
 
0.82 0.473 (0.515) 
q  (C 
 
0.27 
 
0.18 
 
Endurance National 
     
GG 34 72.3 5 71.4 0.833 (0.366) 
GC 11 23.4 2 28.6 
 
CC 2 4.3 - 
  
p (G) 
 
0.84 
 
0.86 0.873 (0.026) 
q  (C 
 
0.16 
 
0.14 
 
Power National 
     
GG 34 77.3 8 72.7 0.246 (2.805) 
GC 5 11.4 3 27.3 
 
CC 5 11.4 - 
  
p (G) 
 
0.83 
 
0.86 0.699 (0.149) 
q  (C 
 
0.17 
 
0.14   
21 
 
21 
 
Table 3. Genotype and allele frequencies of IL6 -174 G/C polymorphism (rs1800795) in Israel (Caucasian) controls (n=205), endurance athletes 
(n=74) and elite power athletes (n=81). 
 
 
 
Controls  
(C) 
Endurance      
(E) 
Power         
(P) 
P (χ2) 
Overall 
P (χ2)                     
C vs. E 
P (χ2)                
C vs. P 
P (χ2)                  
E vs. P 
Genotype        
GG  71.7% (n=147) 71.6% (n=53) 70.4% (n=57) 0.340 (4.520) 0.992 (0.016) 0.132 (4.049) 0.395 (1.860) 
GC 25.9% (n=53) 25.7% (n=19) 22.2% (n=18)     
CC  5% (n=5) 2.7% (n=2) 7.4% (n=6)     
Allele        
p (G) 0.85 0.85 0.82 0.638 (0.899) 0.960 (0.003) 0.357 (0.848) 0.487 (0.484) 
q (C) 0.15 0.15 0.18     
22 
 
22 
 
Table 4. Genotype and allele frequencies of the IL6 -174 G/C polymorphism (rs1800795) 
in Israel (Caucasian) National (n=109), and International athletes (n=46). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 National International P (χ2)                   
Endurance    
Genotype    
GG  70.0% (n=14) 72.2% (n=39) 0.622 (0.950) 
GC 30.0% (n=6) 24.1% (n=13)  
CC  0% (n=0) 3.7% (n=2)  
Allele    
p (G) 0.84 0.85 0.912 (0.012) 
q (C) 0.16 0.15  
    
Power    
Genotype    
GG  76.4% (n=42) 57.7% (n=15) 0.048 (6.074) 
GC 14.5% (n=8) 38.5% (n=10)  
CC  9.1% (n=5) 3.8% (n=1)  
Allele    
p (G) 0.84 0.77 0.304 (1.055) 
q (C) 0.16 0.23  
23 
 
23 
 
 
 
Figure 1. Genotype and allele frequencies of the IL6 -174 G/C polymorphism (rs1800795) in Israel and Spanish (Caucasians) non-athletes 
(controls), elite endurance and power athletes. Note: data from Israel and Spanish are combined.  
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